Cambridge SME developing breath-based diagnostics and VOC sensor technologies for non-invasive disease detection and exposure monitoring.
Owlstone Medical is a Cambridge-based SME specializing in breath-based diagnostics using chemical ionization mass spectrometry and ion mobility spectrometry. They develop sensor technologies that detect volatile organic compounds (VOCs) in breath samples, enabling non-invasive disease detection and monitoring. Within EU projects, they contribute analytical chemistry instrumentation and sensor expertise to large health research consortia focused on precision medicine, occupational health exposure assessment, and AI-driven diagnostics.
IMPACT focused on soft chemical ionization and ion mobility spectrometry techniques; these core capabilities underpin their contributions to health-oriented projects like EPHOR.
EPHOR (their largest funded project at EUR 322K) applies their sensor technologies to measure workplace exposome factors, job exposure matrices, and pathways to non-communicable diseases.
DRAGON applies deep learning and decision support systems to rapid diagnosis, with Owlstone likely contributing breath-based diagnostic data for AI model training.
3TR investigates molecular mechanisms of treatment non-response in autoimmune and inflammatory diseases, using integrative genomics and predictive modeling.
Owlstone Medical entered H2020 through an MSCA training network (IMPACT, 2016) focused purely on advancing ion mobility and chemical ionization mass spectrometry — their core instrumentation science. From 2019 onward, they pivoted sharply toward applying these sensing capabilities in health contexts: autoimmune disease stratification (3TR), occupational exposure monitoring (EPHOR), and AI-powered pandemic diagnostics (DRAGON). The trajectory is clear — from fundamental analytical chemistry toward clinical and public health applications of their sensor technology.
Owlstone Medical is moving from pure instrumentation science into applied health diagnostics, particularly where sensor data meets AI and precision medicine — expect continued focus on non-invasive diagnostic tools.
Owlstone Medical consistently joins as a participant or third-party contributor in large consortia — they have never coordinated an H2020 project. With 132 unique partners across 22 countries, they operate as a specialist technology provider embedded in broad, multi-partner health research networks. This pattern suggests they are reliable domain experts who contribute specific instrumentation and sensing capabilities rather than driving project direction.
Despite only 4 projects, Owlstone Medical has connected with 132 unique partners across 22 countries, reflecting their participation in very large health consortia like 3TR and EPHOR. Their network spans most of Europe with no single geographic concentration.
Owlstone Medical occupies a rare niche as an SME that bridges analytical chemistry instrumentation with clinical health applications. Their proprietary breath analysis and VOC sensing technology is a distinctive asset for any consortium needing non-invasive biomarker detection. For consortium builders, they offer a commercially-driven partner with real product development capability — not just research output — in a field where few SMEs have comparable depth.
